Scientists have tested many types of cancer vaccines—including ones using mRNA—in labs and human trials to see if they can help fight different cancers.
Scientific Claim
Therapeutic vaccines, including mRNA-based approaches, have been widely studied in preclinical and clinical settings for treating various cancers.
Original Statement
“Immunotherapies, particularly therapeutic vaccines, have been widely used in preclinical and clinical studies to treat various cancers.”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design cannot support claim
Appropriate Language Strength
definitive
Can make definitive causal claims
Assessment Explanation
The term 'widely used' is a general descriptor of research activity, not a claim of efficacy. The abstract does not overstate outcomes, and the language is consistent with a narrative review.
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Systematic Review & Meta-AnalysisLevel 1aIn EvidenceQuantifies the number and types of therapeutic vaccines (including mRNA) tested across cancer types in preclinical and clinical trials.
Quantifies the number and types of therapeutic vaccines (including mRNA) tested across cancer types in preclinical and clinical trials.
What This Would Prove
Quantifies the number and types of therapeutic vaccines (including mRNA) tested across cancer types in preclinical and clinical trials.
Ideal Study Design
A systematic review and meta-analysis of clinicaltrials.gov, PubMed, and regulatory databases from 2000–2023, identifying all therapeutic vaccine trials (mRNA, peptide, dendritic cell) across solid tumors, stratified by phase and cancer type.
Limitation: Cannot determine which vaccines were effective—only how many were tested.
Cohort of Clinical TrialsLevel 2bIn EvidenceTracks the trend of mRNA vaccine development in oncology over time.
Tracks the trend of mRNA vaccine development in oncology over time.
What This Would Prove
Tracks the trend of mRNA vaccine development in oncology over time.
Ideal Study Design
A cohort analysis of 500+ cancer vaccine trials registered between 2010–2023, categorizing them by platform (mRNA, viral vector, etc.), cancer type, and phase to assess adoption trends.
Limitation: Does not assess clinical outcomes or safety comprehensively.
Evidence from Studies
Supporting (1)
Key Considerations for a Prostate Cancer mRNA Vaccine.
This study talks about using mRNA vaccines to fight prostate cancer, which is one type of cancer — and it says that scientists have been testing these kinds of vaccines for many cancers, not just this one. So yes, the claim is right.